Drug Profile
Research programme: tuberculosis therapies - ChemDiv/Institut Pasteur Korea
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ChemDiv; Institut Pasteur Korea
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in South Korea
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in USA
- 15 Apr 2009 Preclinical development is ongoing in USA and South Korea